BSE filing, NSE: INDOCO. Summary written from the filing by ALFA Finder's alert engine.
Indoco Remedies Ltd: key numbers
- Share price
- ₹209.50
- Market cap
- ₹1,934 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 60.5×Sector 48.7×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Q2 FY27 Results: Turns Profitable, Net Profit ₹19.5 Cr
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹19.5 Cr
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Board Meeting Date
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
- Value
- ₹0.01 Cr
Other employee stock options announcements
All →Cholamandalam Investment & Finance Company Employee Stock Options
Cholamandalam Investment and Finance allotted 1,20,202 equity shares to employees upon the exercise of stock options. The company will now seek listing for these shares.
Mahindra & Mahindra Employee Stock Options
Mahindra & Mahindra transferred equity shares from its ESOP Trust to employees upon exercise of stock options. This is a routine employee benefit disclosure.
JSW Energy Employee Stock Options
JSW Energy's employee welfare trust transferred 10,044 shares to employees after ESOP option exercises. The off-market transfer was valued at about Rs 0.01 Crore.
- Value
- ₹0.01 Cr
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Raymond Employee Stock Options
Raymond allotted 1,56,784 equity shares to its ESOP Trust under the Raymond Employees Stock Option Plan 2023. Paid-up capital rose to Rs. 66,73,05,150.
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.